0.05). Mide kanserli hastalarin preoperatif tümör "marker" degerlerine göre; CEA, CA 125 ve CA 19-9 seviyeleri benign hastalikli ve kontrol grubuna göre anlamli derecede yüksekti (p<0.05). Mide kanserli hastalarin postoperatif tümör "marker" degerlerine göre ise; CA 125 ve CA 19-9 kontrol grubuna göre yüksek (p<0.05) iken benign hastalikli grubla karsilastirildiginda sadece CA 125 seviyesi anlamli olarak yüksek (p<0.05) bulundu. Benign hastalikli grup ile kontrol grubu arasinda; preoperatif tümör "marker" degerleri yönünden anlamli fark bulunmadi (p>0.05). Postoperatif degerler arasinda ise CA 19-9 benign hastalikli grubda anlamli bulundu (p<0,01). Mide kanserli olgularda AFP'in spesifitesi %100, sensitivitesi %3.5 iken CEA'in spesifitesi %100, sensitivitesi %63; CA 125'in spesifitesi %96, sensitivitesi %63; CA 19-9'un spesifitesi %100, sensitivitesi %47 olarak bulundu. Mide kanserlerinin teshisinde; CEA, CA 125, CA 19-9'un duyarli oldugu, postoperatif takip gibi klinik degerlendirmede özellikle CA 125 ve CA 19-9 'un prognostik degerlerinin daha fazla oldugu sonucuna varildi. In this study, we aimed to investigate; diagnostic usefulness and sensitivity-specisifity values of some of the tumor markers (such as:CEA, CA 19-9, CA 125, and AFP) in totally 112 patients (75 male, 37 female) with gastric cancer. Gastric cancer group; the 57 patients (38 male, 17 female) mean age 55.36±1.37 years, benign disease group; the 30 patients (20 male, 10 female) mean age 53.53±1.97 years, control group; the 25 healtly (17 male, 8 female) mean age 57.11±2.87 years. No statistical significant difference was found between the groups for age and sex (p>0.05). Preoperative tumor marker values; CEA, CA 125 and CA 19-% levels in gastric cancer group were found to be highly significiant among benign disease and control groups (p<0.05). Postoperative tumor marker values; CA 125 and CA 19-9 levels in gastric cancer group were found to be highly significant control group (p<0.05), but only CA 125 level were found to be highly significant benign disease group (p<0.05). Preoperative tumor marker value; No statistical significant difference was found between benign disease group and control group from all of the tumor marker levels (p>0.05). Postoperative tumor marker values; CA 19-9 levels in benign disease group were found to be highly significant control group (p<0.01). The sensitivity and specificity of AFP were 3.5-100%, sensitivity and specificity of CEA were 63-100%, sensitivity and specificity of CA 125 were 35-96%, sensitivity and specificity of CA 19-9 were 47-100% in gastric cancer, respectively. In conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up etc.) of gastric cancers."> [PDF] Mide kanserli olgularda tümör "marker"larında AFP, CEA, CA 125 ve CA19-9'un klinik kullanımlarının incelenmesi | [PDF] The clinical usefulness of the tumor markers; AFP, CEA, CA 125 and CA 19-9 in patients with gastric cancer 0.05). Mide kanserli hastalarin preoperatif tümör "marker" degerlerine göre; CEA, CA 125 ve CA 19-9 seviyeleri benign hastalikli ve kontrol grubuna göre anlamli derecede yüksekti (p<0.05). Mide kanserli hastalarin postoperatif tümör "marker" degerlerine göre ise; CA 125 ve CA 19-9 kontrol grubuna göre yüksek (p<0.05) iken benign hastalikli grubla karsilastirildiginda sadece CA 125 seviyesi anlamli olarak yüksek (p<0.05) bulundu. Benign hastalikli grup ile kontrol grubu arasinda; preoperatif tümör "marker" degerleri yönünden anlamli fark bulunmadi (p>0.05). Postoperatif degerler arasinda ise CA 19-9 benign hastalikli grubda anlamli bulundu (p<0,01). Mide kanserli olgularda AFP'in spesifitesi %100, sensitivitesi %3.5 iken CEA'in spesifitesi %100, sensitivitesi %63; CA 125'in spesifitesi %96, sensitivitesi %63; CA 19-9'un spesifitesi %100, sensitivitesi %47 olarak bulundu. Mide kanserlerinin teshisinde; CEA, CA 125, CA 19-9'un duyarli oldugu, postoperatif takip gibi klinik degerlendirmede özellikle CA 125 ve CA 19-9 'un prognostik degerlerinin daha fazla oldugu sonucuna varildi."> 0.05). Mide kanserli hastalarin preoperatif tümör "marker" degerlerine göre; CEA, CA 125 ve CA 19-9 seviyeleri benign hastalikli ve kontrol grubuna göre anlamli derecede yüksekti (p<0.05). Mide kanserli hastalarin postoperatif tümör "marker" degerlerine göre ise; CA 125 ve CA 19-9 kontrol grubuna göre yüksek (p<0.05) iken benign hastalikli grubla karsilastirildiginda sadece CA 125 seviyesi anlamli olarak yüksek (p<0.05) bulundu. Benign hastalikli grup ile kontrol grubu arasinda; preoperatif tümör "marker" degerleri yönünden anlamli fark bulunmadi (p>0.05). Postoperatif degerler arasinda ise CA 19-9 benign hastalikli grubda anlamli bulundu (p<0,01). Mide kanserli olgularda AFP'in spesifitesi %100, sensitivitesi %3.5 iken CEA'in spesifitesi %100, sensitivitesi %63; CA 125'in spesifitesi %96, sensitivitesi %63; CA 19-9'un spesifitesi %100, sensitivitesi %47 olarak bulundu. Mide kanserlerinin teshisinde; CEA, CA 125, CA 19-9'un duyarli oldugu, postoperatif takip gibi klinik degerlendirmede özellikle CA 125 ve CA 19-9 'un prognostik degerlerinin daha fazla oldugu sonucuna varildi. In this study, we aimed to investigate; diagnostic usefulness and sensitivity-specisifity values of some of the tumor markers (such as:CEA, CA 19-9, CA 125, and AFP) in totally 112 patients (75 male, 37 female) with gastric cancer. Gastric cancer group; the 57 patients (38 male, 17 female) mean age 55.36±1.37 years, benign disease group; the 30 patients (20 male, 10 female) mean age 53.53±1.97 years, control group; the 25 healtly (17 male, 8 female) mean age 57.11±2.87 years. No statistical significant difference was found between the groups for age and sex (p>0.05). Preoperative tumor marker values; CEA, CA 125 and CA 19-% levels in gastric cancer group were found to be highly significiant among benign disease and control groups (p<0.05). Postoperative tumor marker values; CA 125 and CA 19-9 levels in gastric cancer group were found to be highly significant control group (p<0.05), but only CA 125 level were found to be highly significant benign disease group (p<0.05). Preoperative tumor marker value; No statistical significant difference was found between benign disease group and control group from all of the tumor marker levels (p>0.05). Postoperative tumor marker values; CA 19-9 levels in benign disease group were found to be highly significant control group (p<0.01). The sensitivity and specificity of AFP were 3.5-100%, sensitivity and specificity of CEA were 63-100%, sensitivity and specificity of CA 125 were 35-96%, sensitivity and specificity of CA 19-9 were 47-100% in gastric cancer, respectively. In conclusion, tumor markers, especially CA 125 and CA 19-9 can be used in clinical applications (e.g. diagnosis, preoperative evaluation and follow up etc.) of gastric cancers.">

Ulaşmaya çalıştığınız dergi veri tabanımızda bulunmamaktadır. Detaylı bilgi için lütfen editörle iletişime geçiniz, acarindex@gmail.com